BridgeBio Pharma (BBIO) Net Cash Flow Growth (1y) (2019 - 2026)
BridgeBio Pharma (BBIO) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,899.87 Bn | 1,899.81 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.43 Bn | 465.64 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.43 Bn | 116.19 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.20 Bn | 61.44 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 61.75 Bn | 61.75 Bn | - | - |
| 8 | Argenx Se | 56.15 Bn | 50.96 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 53.46% |
| 10 | BridgeBio Pharma | 16.69 Bn | 15.75 Bn | 184.58 Mn | 320.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 320.55% |
| Dec 31, 2025 | -126.49% |
| Sep 30, 2025 | 25.16% |
| Jun 30, 2025 | 189.33% |
| Mar 31, 2025 | -269.76% |
| Dec 31, 2024 | 312.79% |
| Sep 30, 2024 | -171.00% |
| Jun 30, 2024 | 165.19% |
| Mar 31, 2024 | 354.12% |
| Dec 31, 2023 | -87.82% |
| Sep 30, 2023 | 1,418.35% |
| Jun 30, 2023 | -212.20% |
| Mar 31, 2023 | 182.20% |
| Dec 31, 2022 | -132.30% |
| Sep 30, 2022 | 106.63% |
| Jun 30, 2022 | 206.27% |
| Mar 31, 2022 | -119.26% |
| Dec 31, 2021 | 2,548.19% |
| Sep 30, 2021 | -13.85% |
| Jun 30, 2021 | 57.13% |